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Lignocellulosic biomass is a massive, but largely unexploited potential source of biofuel.  
The underutilization of this resource stems largely from the fact that cellulose is difficult to 
digest into smaller, useable sugar units.  Natural lignocellulosic biomass is primarily degraded by 
fungi, which use Family 1 carbohydrate-binding modules (CBMs) to target cellulose for 
degradation.  Family 1 CBMs are glycosylated, but the effects of glycosylation on CBM function 
remain unknown. Here, the effects of O-mannosylation of the Family 1 CBM from the 
Trichoderma reesei Family 7 cellobiohydrolase (TrCel7A) are investigated at three glycosylation 
sites, Thr-1, Ser-3 and Ser-14.  The work was made possible by the development of a convenient 
one-pot synthetic procedure for glycosylated Family 1 CBMs. A library of 20 CBM glycoforms 
was synthesized with mono-, di-, or tri-saccharides at each glycosylation site.  The binding 
affinity, proteolytic stability, and thermostability of each synthetic glycoform was systematically 
studied. The results show that even though CBM mannosylation does not induce significant 
changes to the protein’s secondary structure, it can increase the thermolysin cleavage resistance 
up to 50-fold.  Fungi are known to excrete several proteases along with CBM-bearing cellulases, 
so improved proteolytic stability may improve cellulose digestion efficiency by reducing CBM 
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degradation.  O-mannosylation was also shown to increases the thermostability of CBM 
glycoforms up to 16°C, and a mannose disaccharide at Ser3 has the largest themostabilizing 
effect. Thermostability is an important property of industrial enzymes because bioreactors are 
often operated at elevated temperatures. In the binding affinity tests, the glycoforms with small 
glycans at each site displayed the highest binding affinities for crystalline cellulose, and the 
glycoform with a single mannose at each of the three positions had the highest binding affinity; a 
7.4 fold increase compared to the unglycosyalted CBM.  High CBM binding affinity has been 
linked to increased cellulose digestion rate by fungal cellulases, so these results may have 
important implications in biofuels production.  This study demonstrated how chemical synthesis 
can be used to systematically study glycosylation and lead to the identification of two CBM 
glycoforms with particularly desirable stability and binding properties. 
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CHAPTER 1 
 
INTRODUCTION 
 
 
 
1.I. Chemical Synthesis as a Tool to Study Glycosylation   
 
Most proteins undergo some form of covalent post-translational modification.  These 
modifications greatly increase the diversity and functional repertoire of proteins.  Glycosylation, 
the attachment of sugars through covalent linkages, is one of the most common post-translational 
modifications, and at least one-half of human proteins are glycosylated.
1
  Compared to other 
post-translational modifications such as phosphorylation, glycosylation is not very well 
understood, but it is thought to affect many properties of proteins including: biological activity, 
solubility, thermostability, and susceptibility to degradation and aggregation.
2
  
Glycosylation is not under direct genetic control and glycosylation patterns are highly 
dependent on local cellular conditions.
3
 The result is that different glycosylated forms 
(glycoforms) of the same protein are often observed within the same organism.  It is possible that 
only one of the many glycoforms of a protein has the desired biological function.
4
  As a result, it 
can be difficult to decipher the effects of glycosylation by studying complex biological mixtures 
of glycoforms.  Abnormal glycosylation states of several proteins have been shown to be 
indicative of disease,
3
 so the ability to study individual glycoforms could prove to be invaluable. 
 Unfortunately, it is difficult to separate homogeneous glycoforms from biological 
mixtures and, as a result, it is often only possible to study mixtures of glycoforms using 
biological expression.  Many such studies have been conducted, but they usually only provide an 
estimate of the average properties and activities of the glycoforms in a complex mixture.  Due to 
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the constant variations in the composition of glycoform mixtures, the results of such studies are 
often fragmented or inconsistent.2,5 The ability to isolate individual glycoforms for study would 
alleviate these problems and allow for the systematic study of glycosylation.  Fortunately, 
chemical synthesis has emerged as a powerful approach to prepare homogeneous peptide and 
protein glycoforms.6–8 The synthesis of glycoproteins is more expensive and time consuming 
than biological expression, but it allows for precise control of glycan structure and makes the 
incorporation of glycans at unnatural glycosylation sites relatively simple.   In principle, 
chemical synthesis could allow access to any of the glycosylated forms of a protein, which, in 
turn, would allow the detailed study of the properties of any glycoform.
9,10
  
 
1.II. Biofuels Production and Lignocellulose-Degrading Enzymes 
 
Cellulose is the most abundant, renewable source of reduced carbon in the biosphere. It 
has been targeted for use in biofuel production, but the difficulties associated with breaking 
down cellulose crystals into usable fuel sources have made biofuel production from cellulosic 
biomass relatively inefficient.11 For this reason, the development of biological systems for the 
conversion of cellulose into economical ethanol based fuels has attracted significant interest.11,12  
Most of the plant biomass on our planet is degraded by fungi and bacteria, which secrete 
synergistic cocktails of enzymes that work in concert to degrade polysaccharides.
11,13
 The mono 
and di-saccharide products of these enzymes can be converted into ethanol for biofuels quite 
easily by other microorganisms, but the initial degradation of cellulose polymers is usually quite 
slow, creating a bottleneck in biofuels production.  As a result, the study of lignocellulose-
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degrading enzymes has become a priority so that ways to increase their efficiency can be 
identified. 
 The lignocellulose-degrading enzymes of bacteria and fungi are often multi-modular, 
consisting of one or more catalytic domains
11,13–17
 linked to a carbohydrate-binding module 
(CBM) that targets plant cell wall polysaccharides through various means.
18
 Carbohydrate-
binding modules are quite common in nature.  To date, 67 CBM families have been identified
19
  
and many of them are thought to play important roles in the degradation of biomass. The 
majority of fungal lignocellulose-degrading enzymes that have CBMs have Family 1 CBMs
19
  
which are small protein domains consisting of less than 40 amino acids.  Kraulis et al. solved the 
first Family 1 CBM NMR structure of the well-characterized glycoside hydrolase (GH) Family 7 
cellobiohydrolase from the fungus Trichoderma reesei (Hypocrea jecorina), or TrCel7A.
20
 The 
structure of the TrCel7A CBM is a β-sheet rich structure with two disulfide bridges and a flat 
face formed by aromatic and polar side chains that is believed to be responsible for cellulose 
binding (Figure 1.1).
20–23
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Figure 1.1. The NMR structure of the Family 1 CBM and the top layer of cellulose (11) 
The hydrophobic binding face is formed by the three tyrosine residues shown in purple.  The 
three potential glycosylation sites examined in this study are displayed with attached mannoses 
shown in blue. 
 
 
 
1.III. Glycosylation of Lignocellulose-Degrading Enzymes 
 
Fungal enzymes that degrade biomass are often heavily glycosylated.
24,25
 Unfortunately, 
few studies have been conducted on glycosylation in secreted fungal enzymes.  In most cases, 
the extent of lignocellulose-degrading enzyme glycosylation and the factors that control it are 
unknown. Growth conditions and extracellular glycan-trimming enzymes alter glycosylation 
patterns so these factors must be carefully controlled if detailed studies are to be performed.  
All of the domains of TrCel7A have been observed to be glycosylated in nature.  
Catalytic domains have been observed with both N- and O-linked glycans,
26,27
 but the linkers 
connecting enzymatic domains to CBMs have only been observed to have O-linked 
glycosylation. Linker glycosylation is thought to provide protease protection
28
 and may possibly 
be involved in substrate binding.
29
 For TrCel7A, Harrison et al. published the original 
characterization of the glycosylation pattern on the TrCel7A linker.
30
 The last five residues 
  
5 
 
analyzed in their study (TQSHY) form the N-terminus of the CBM, and the threonine and serine 
residues (Thr1, Ser3, respectively) were shown to both natively exhibit mannosylation.
30
 Since 
these residues are highly conserved, the observed mannosylation is probably common in Family 
1 CBMs.
31
 It is also possible that the highly conserved Ser14 residue is naturally mannosylated, 
but this has not been experimentally characterized. Free energy calculations predict that the 
mannosylation at Thr-1, Ser-3 and Ser-14 will improve the CBM binding affinity to crystalline 
cellulose.
32
 Furthermore, these calculations suggest that the glycan structure, location, and the 
number of occupied glycosylation sites will impact the affinity of CBMs for crystalline 
cellulose.
32
 These computational results justified the systematic study of TrCel7A CBM 
glycosylation. 
To this end, a series of synthetic glycoforms with systematic alterations in glycosylation 
patterns were produced using chemical glycoprotein synthesis.  This small library of CBM 
glycoforms allowed for the systematic study of the effects of glycosylation on CBM stability and 
function.  The library was constructed so that the effect of glycosylation at each site could be 
studied independently and in the presence of glycans at other sites to determine the effect of 
glycoslation at each site and to explore the possibility of synergistic effects from glycosylation at 
multiple sites.  The results of this study should greatly augment the existing knowledge of a 
protein domain that plays an important role in biomass degradation, and, potentially, biofuels 
production. 
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CHAPTER 2 
 
CHEMICAL SYNTHESIS 
 
 
2.I. Introduction 
 
 In order to efficiently produce the library of synthetic CBM glycoforms used in this 
study, a facile, one-pot synthetic method was developed.  The method, which was developed by 
Dr. Liquin Chen,
33,34
 utilized 9-Fluorenylmethoxycarbonyl (Fmoc)-based solid phase peptide 
synthesis (SPPS) and mannosylated Fmoc amino acid building blocks.  Once optimized, the 
method allowed for each CBM glycoform to be produced in high purity in less than a week.  
Multiple glycoforms could be synthesized simultaneously and one researcher could reasonably 
produce up to three a week. 
 The synthetic approach described herein demonstrates how chemical synthesis can be 
used to rapidly generate libraries of homogenous small protein glycoforms for comparison 
studies.  Depending on the size and sequence of the protein and the size and complexity of the 
glycans, the synthetic procedure may take a considerable amount of time to optimize, but once it 
is the preparation of the glycoforms is fairly facile.  For instance, our CBM synthesis took 
several months to optimize, but after optimization, an individual glycoform could be produced 
by an undergraduate chemist in about a week.  The synthesis optimization time is expected to be 
reduced as scientists gain more experience and knowledge of glycoprotein synthesis, so this sort 
of synthetic approach can be expected to become even more efficient in years to come. 
 
2.II. A One-Pot Method for CBM Synthesis and Folding 
2.II.a. Solid Phase Peptide Synthesis 
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Fmoc-based SPPS was used in the synthesis of the CBM glycoforms because of its 
compatibility with acid-sensitive glycosidic bonds.35 The glycoforms were synthesized using 
preloaded trityl resin (Fmoc-Leu-NovaSyn® TGT), and the mannosylated Fmoc amino acid 
building blocks (Fig. 2).36  Extended coupling times were used for the mannosylated amino acids 
to ensure complete coupling. 
The initial SPPS resulted in incomplete coupling at Val-18, but a pseudoproline dipeptide 
strategy36 using Fmoc-Ala-Ser(psiMe,Mepro)-OH (shown in Figure 2.1 on the following page) 
was used to solve the problem.  The dipeptide presumably induced a conformational change in 
the growing peptide chain that allowed for complete coupling at Val-18.  After SPPS, the peptide 
was cleaved from the resin and side-chain protecting groups were removed by stirring in 
95:2.5:2.5 TFA:TIS:H2O.  The unprotected peptides were then lyophilized and used in the 
mannose deprotection and folding reactions without purification. 
 
2.II.b. Mannose Deprotection and Folding 
 
The acetyl protecting groups on the mannose residues were removed in 30 min by stirring 
in 5% hydrazine. The deprotected glycoforms were folded by direct dilution in a mixed 
glutathione-folding buffer and stirring overnight.
37
 The folding products were purified with 
reverse phase high performance liquid chromatography (HPLC) and lyophilized.  The isolated 
yields varied from 30% for the unglycosylated CBM to 3% for the CBM with three attached 
mannose trisaccharides.  In general, more heavily glycosylated CBM glycoforms had lower 
synthetic yields. 
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2.II.c. CBM Glycoform Library 
 
 The procedure described above was used to synthesize a total of 20 CBM glycoforms for 
systematic study.  The structures of the glycoforms are illustrated in Figure 2.1. 
 
 
 
 
Figure 2.1. The library of CBM glycoforms synthesized for this study.  The amino acid 
building blocks, glycosylation sites, glycan structures and disulfide linkages are also shown. 
 
The library contains the unglycosylated protein, a systematic series of mono-glycosylated 
analogs (glycoforms 1 through 10 in Figure 2.4) and a series of multiply glycosylated analogs.  
The mono-glycosyalted analogs allowed for the assessment of the site-specific effects of 
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glycosylation and the multiply glycosylated analogs allowed for the analysis possible additive or 
synergistic effects of multiple glycosylation.  Together, the library of synthetic CBM glycoforms 
allowed for the systematic study of CBM glycosylation, which would not be possible using 
biological mixtures. 
 
2.II.d. Product Verification 
 
In order to confirm the disulfide linkages, the unglycosylated CBM was digested with 
thermolysin and the resulting fragments were analyzed using LCMS.  As shown in Figure 2.5, 
the peptide fragments that were observed for the digest were consistent with the appropriate 
disulfide bond pattern (C8 to C25 and C19 to C35). Importantly, the peptide fragments that 
would have resulted from incorrect disulfide bond connectivity were not observed.  Therefore, it 
is reasonable to conclude that the disulfide connectivity of the unglycosylated CBM product was 
consistent with the natural protein.  Since the TrCel7A Family 1 CBM is a small protein domain 
with 2 disulfide bonds, correct disulfide connectivity strongly suggests that the molecule folded 
correctly. 
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Figure 2.2. Determination CBM disulfide binding by thermolysin digestion.  Cleavage sites 
are indicated by arrows and key fragment peaks are indicated in the mass spectra. 
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Glycoform identity and purity were experimentally verified by liquid chromatography–
mass spectrometry (LC-MS).   The LC-MS traces of the purified glycoforms showed a single 
major peak with the mass of the folded CBM anlogs.  LC-MS can distinguish between 
differently folded proteins with the same mass, so the presence of a single peak in the LCMS 
trace further provides evidence that the products contained only the correctly folded desired 
glycoforms.  A representative LC-MS trace and ESI mass spectra (for CBM 2) is shown here in 
Figure 2.6.  The LC-MS traces and ESI mass spectra for every CBM glycoform are available in 
Appendix 3. 
 
 
Figure 2.3. The LC-MS trace and ESI-MS of a representative CBM glycoform (CBM 2).  
MS (ESI) Calcd for C165H245N43O59S4: [M+2H]
2+
 m/z = 1951.32, [M+3H]
3+
 m/z = 1301.21, 
[M+4H]
4+
 m/z = 976.16. 
 
 
Next, the secondary structure of the CBM analogs was analyzed using far-UV circular 
dichroism (CD) spectroscopy.  Far-UV CD provides valuable information on the secondary 
structure of peptides and proteins.  The CD spectrum of the unglycosylated CBM was very 
similar to the spectrum of the unglycosylated molecule presented in literature,
38
 which further 
supports the conclusion that the analog was properly folded.  The spectra of most of the analogs 
are quite similar.  They have a large flat depression centered at about 217 nm and a positive peak 
at about 205 nm, which are consistent with a peptide/protein that adopts predominantly β-sheet 
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secondary structure (as the CBM does).  These results indicate that glycosylation does not cause 
major secondary structure changes in most of the analogs, which isn’t particularly surprising 
because all three glycosylation sites are in loop or turn regions which are on the exterior of the 
small peptide.   Importantly, O-mannosylation at Thr-1, Ser-3, and Ser-14 sites does not appear 
to impair CBM folding.  The CD spectra of the 20 CBM glycoforms synthesized in this study are 
provided in Figure 2.7 below.  They are fairly similar, with the primary difference being a lower 
peak at ~204 nm for some glycoforms, suggesting a larger fraction of unordered structure for 
those glycoforms.  The increase in unordered structure could be investigated with H/D exchange. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. The CD spectra of the 20 TrCel7A CBM glycoforms.  All spectra were acquired in 
10 mM NaOAc buffer with a pH = 5.2 at 20 °C. 
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The resulting CD spectra were used to calculate the secondary structure fractions of each 
CBM analog using the CDPro software provided by Colorado State University. The secondary 
structure fractions of each CBM analog are fairly similar, supporting the notion that 
glycosylation at Thr-1, Ser-3 and Ser-14 only slightly changes the conformation.  The secondary 
structure fractions are shown in Table 2.1 below.  It does appear that glycosylation slightly 
decreases the amount of β-sheet structure and increases the amount of “unordered” structure, 
with more heavily glycosylated analogs generally having less β-sheet structure.  Therefore, it can 
be concluded that CBM glycosylation does not prevent folding but it does slightly disrupt the β-
sheet structure of the protein. 
 
Table 2.1. The secondary structure percentages of each CBM glycoform.  Calculated from 
the CD spectra shown in Figure 2.4. 
 Secondary Structure Percent 
CBM 
Variant 
 
Β-Sheet 
 
α-helix 
 
Turn 
 
Unordered 
1 43.4 2.4 22.9 29.3 
2 34.9 3.0 24.0 36.4 
3 30.9 1.7 25.6 41.8 
4 30.9 0.7 25.2 42.6 
5 27.3 0.5 25.1 46.3 
6 35.1 0.2 23.5 38.2 
7 33.7 0.6 25.1 39.6 
8 30.3 1.3 25.7 42.5 
9 28.6 1.4 26.1 43.4 
10 28.6 0.9 25.9 44.0 
11 33.5 ~0 23.3 37.0 
12 30.6 1.3 24.9 42.5 
13 34.2 2.9 23.0 37.6 
14 32.3 0.1 25.8 36.2 
15 35.3 0.5 23.3 37.7 
16 32.3 ~0 25.5 42.3 
17 34.1 1.6 24.9 38.4 
18 34.1 1.6 25.1 38.2 
19 34.2 0.7 24.5 40.1 
20 34.6 0.8 24.7 39.4 
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2.II.e. Materials and Methods 
 
All commercial reagents and solvents were used as received. Unless otherwise noted, all 
reactions and purifications were performed under air atmosphere at room temperature. All LC-
MS analyses were performed using a Waters Acquity
TM
 Ultra Performance LC system equipped 
with Acquity UPLC® BEH 300 C4, 1.7μm, 2.1 x 100 mm column at flow rates of 0.3 and 0.5 
mL/min. The mobile phase for LC-MS analysis was a mixture of H2O (0.1% formic acid, v/v) 
and acetonitrile (0.1% formic acid, v/v). All preparative separations were performed using a 
LabAlliance HPLC solvent delivery system equipped with a Rainin UV-1 detector and a Varian 
Microsorb 100-5, C18 250x21.4mm column at a flow rate of 16.0 mL/min. The mobile phase for 
HPLC purification was a mixture of H2O (0.05% TFA, v/v) and acetonitrile (0.04% TFA, v/v). A 
Waters SYNAPT G2-S system was used mass spectrometric analysis.    
Solid-phase peptide synthesis was performed on a PioneerTM Peptide Synthesis System. 
Peptides and glycopeptides were synthesized by Fmoc chemistry on a pre-loaded Fmoc-Leu-
Novasyn® TGT resin. The following Fmoc amino acid building blocks and pseudoproline 
dipeptides from Chem-Impex, EMD Millipore, and AAPPTec were used in the synthesis: Fmoc-
Asn(Trt)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Gly-OH, Fmoc-His(Trt)-OH, 
Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Pro-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-
Tyr(tBu)-OH, Fmoc-Val-OH, and Fmoc-Ala-Ser(psiMe,MePro)-OH. Synthetic cycles were 
completed with a standard coupling time of 15 min using Fmoc protected amino acids (4 eq.), 2-
(1H-7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uroniumhexafluorophosphatemethan aminium 
(4 eq.) and N,N-diisopropylethylamine (8 eq), except for a prolonged coupling time of 2 h for 
glycoamino acids. The deblocking was performed by mixing with DMF:piperidine:1,8-
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Diazabicyclo[5.4.0]undec-7-ene (100:2:2, v/v/v) for 5 min. Upon completion, the resin was 
washed into a peptide cleavage vessel with dichloromethane. Cleavage and side-chain 
deprotection was performed by treatment with TFA:H2O:triisopropylsilane (95:2.5:2.5, v/v/v) 
solution for 45 min. The filtered cleavage mixture was then concentrated using a gentle stream of 
air and precipitated at 0 °C by the addition of cold diethyl ether. After centrifugation, the 
resulting pellet was dissolved in H2O:acetonitrile (1:1, v/v) and lyophilized to dryness for further 
use. 
The acetyl groups of the mannose resiudes were removed by stirring the unpurified 
synthetic glycopeptides in a hydrazine solution (hydrazine:H2O, 5:100, v/v) at room temperature 
for 30 min under helium atmosphere. The final concentration of the glycopeptides was 4 mM. 
The reaction was quenched with a solution of AcOH (AcOH:H2O, 5:100, v/v) and the pH was 
adjusted to ~8.  The folding was initiated by diluting the unprotected glycoforms to a final 
concentration of ~0.05 mM in a folding buffer (0.2 M Tris-acetate, 0.33 mM oxidized 
glutathione, 2.6 mM reduced glutathione, pH 8.2). The folding solution was stirred at room 
temperature for 12 h under helium atmosphere. The solution was then concentrated to a small 
volume (3-5 mL) using 3 kDa cut-off centrifugal filter units (Amicon) before RP-HPLC 
purification. The HPLC purification was performed on a Versagrad Preparation-HPLC system 
using a semi-preparative C-18 column. The products were detected by UV absorption at 275 nm. 
The details of the Thermolysin digestion are as follows:  Lyophilized Thermolysin, from 
Bacillus thermoproteolyticusrokko, was purchased from Promega Corporation. The digestion 
was performed in a 50 mM Tris-HCl buffer (pH = 8) with 0.5 mM CaCl2 at a temperature of 37 
°C. The reaction was performed in 100 µL of solution with an initial concentration of 270 µM. 
The solution was prepared so that CBM and thermolysin were initially present in a 20:1 molar 
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ratio. The reaction was monitored over time by taking 10 µL aliquots and quenching them with 
an equal volume of 5% AcOH. The aliquots were analyzed using the Waters Acquity UPLC and 
a Waters SYNAPT G2-S mass spectrometer. 
All CD spectra were acquired using an Applied Photophysics Chirascan
TM
-plus CD 
spectrometer. In all cases, the spectra were acquired in a 0.5 mm quartz cuvette under nitrogen at 
a flow rate of 1 L/min. Each CBM analog was dissolved in 10 mM NaOAc buffer with a pH of 
5.2. The peptide concentration was 0.2 mg/mL in all tests. CD spectra were obtained at 20 °C 
with a step of 0.5 nm, 0.5 s per point and a spectral width of 200-240 nm. The spectra are the 
average of 4 scans with an averaged 4 scan buffer baseline subtracted. The resulting CD spectra 
were used to calculate the secondary structure fractions of each CBM analog using the CDPro 
software provided by Colorado State University. The secondary structure fractions of each CBM 
analog are the average of the results of the three CDPro programs (SELCON3, CDSSTR and 
CONTIN). 
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CHAPTER 3 
STABILITY STUDIES 
 
3.I. Introduction 
 
 While performing the thermolysin digests to determine disulfide bond connectivity, it was 
observed that the digestion of some analogs proceeded much more rapidly than others.  
Glycosylation is known to increase the proteolytic stability of some proteins,2 so it seemed 
reasonable to investigate if it does so with the CBM glycoforms.  Improving the proteolytic 
stability of cellulases, and their CBMs, may be beneficial to biofuel production.  The secretome 
of T. reesei includes a host of proteolytic enzymes, some of which are active under neutral 
conditions.
39–43
  Although these proteolytic enzymes are favorable for biomass conversion since 
they degrade structural proteins of plants, they also degrade cellulases, which can slow cellulose 
degradation.
39–44
  Glycosylation may improve the proteolytic stability of the CBM (and the 
cellulase as a whole), which could lead to more efficient cellulose degradation in biofuels 
production.  Thermolysin digests were performed for each CBM analog and the disappearance of 
the molecular ion peaks were tracked over time.  These tests made it possible to determine if 
glycosylation at certain sites improved the proteolytic stability of the CBM glycoforms. 
 Cellulase thermostability is important because performing biofuel fermentations at high 
temperatures increases reaction rates and protects mixtures from microbial contamination.
12,45,46
  
Recently, the CBM of Cel7A was shown to increase the thermostability of the Cel7A enzyme, 
and chimeric cellulases with CBMs have also acquired positive thermostabilizing effects.
47,48
 
Based on these results, it is reasonable to theorize that increasing the thermostability of the CBM 
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could improve the thermostability of the cellulase.  Glycosylation has been shown to increase the 
thermostability of some proteins,49 so the thermostability of the 20 CBM glycofoms was 
investigated using variable temperature circular dichroism to determine if CBM glycosylation 
has a stabilizing effect.   
 
3.II. Proteolytic Stability 
 
3.II.a. Experimental Design 
 
The CBM glycoforms were digested by thermolysin at 37 °C.  Samples were taken at set 
time intervals for mass analysis.  The digestion rate was determined by monitoring the loss of 
intensity of the molecular ion peak over time using electrospray ionization (ESI) mass 
spectrometry.   Unfortunately, the initial studies yielded inconsistent results, possibly due to the 
sensitivity of ESI to the salt ions in the digestion buffer.  In order to solve this problem, matrix 
assisted laser desorption/ionization (MALDI) mass spectrometry, which is less sensitive to salt 
ions, was used to monitor the disappearance of the CBM analogs during digestion.  MALDI is 
not normally thought of as a quantitative mass spectrometry technique, but, with the use of 
appropriate internal standards, it has been shown the technique can provide reliable quantitative 
results.50,51 An appropriate internal standard is structurally similar to the molecule of interest so 
that it will have similar ionization properties, but it must have a different mass to be observed as 
a separate peak.  Fortunately, the small library of CBM glycoforms could be used as internal 
standards for each other.   Concentration calibration curves were produced over the concentration 
ranges that were monitored during digestion studies.  The mass spectra of the digest samples 
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were compared to the calibration curves to determine the change in intact CBM glycoform 
concentration over time.  The technique proved to be quite robust, and it was able to monitor 
CBM glycoform concentrations down to below 1 µM.  The data from the digestions were fit to 
exponential decay functions to determine the half-life of each glycoform in thermolysin. Figure 
3.1 shows the data and exponential decay fit for the digest study of the unglycosylated CBM as 
an example. 
 
 
Figure 3.1. The results of the thermolysisn digest of CBM1.  The adjusted intensity of each 
point is the intensity of the sample molecular ion divided by that of the internal standard.  The 
exponential decay fit line and equation that were used to calculate the half-life are displayed. 
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3.II.b. Results and Discussion 
 
Comparison of the thermolysin half-lives of the nine mono-glycosylated CBMs to the 
unglycosylated CBM in Figure 3.1A reveals an interesting trend.    
 
 
 
Figure 3.2. The thermolysin half-lives of the 20 CBM glycoforms. A) The nine mono-
glycosylated CBM glycoforms divided by glycosylation site. B) The multiply-glycosylated CBM 
based on additional glycosylation of glycoforms 5 and 6.  C) The three CBM glycoforms with all 
three glycosylation sites occupied by the same glycans.  The bars with the hatched pattern 
represent glycoforms with the best overall (stability and binding) properties. 
 
 
Glycosylation at Thr-1 did not increase the proteolytic stability of the molecule at all, 
glycosylation at Ser-14 increased the proteolytic stability a little, and glycosylation at Ser-3 had a 
large impact on the proteolytic stability.  The nonglycosylated CBM 1 has a thermolysin half-life 
of about 0.2 h, whereas the Ser-3 glycosylated CBM variants, 6 and 7, have half-lives of more 
than 2 h, an increase of over 10-fold.  The greatly increased proteolytic stability from Ser-3 
glycosylation is likely due to the site’s proximity to a thermolysin cleavage site (see Figure 2.5).  
Glycosylation so close to the cleavage site may directly shield the protein backbone from 
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cleavage or sterically hinder protease approach.  Thr-1 and Ser-14 are farther away from 
thermolysin cleavage sites (see Figure 2.5), so it is not surprising that glycosylation at those sites 
has less of a protective effect.  Increasing the size of the glycan on Ser-3 from the 
monosaccharide to a disaccharide increased the half-life from 1 hour to 2 hours, but going from 
the disaccharide to the trisaccharide did not increase the half-life.  Therefore, glycan size does 
appear to increase the half-life up until a point.   
Figure 3.1 B shows the multiply glycosylated CBM glycoforms formed by adding 
additional glycans to the Ser-3 glycosylated glycoforms 5 and 6.  It is apparent that adding 
glycans to Thr-1 and Ser-14 after Ser-3 is already glycosylated can greatly increase the 
proteolytic half-life (up to 11 hours for glycoform 14).  This large increase is interesting because 
Thr-1 and Ser-14 glycosylation on their own have only a small impact on proteolytic stability.  It 
is possible that the multiply glycosylated analogs adopt a fold that is less susceptible to 
proteolytic degradation. 
 Interestingly, the most heavily glycosylated CBM glycoform (CBM 20 in Figure 3.1 C), 
did not have the longest half-life (CBM 20’s half-life is only 6 hours compared to the 11 hour 
half-life of CBM 14).  One possible explanation is that too much glycosylation partially undoes 
the protective effect by disrupting the protein fold, and potentially exposing more or better 
cleavage sits to the protease.  This hypothesis is supported by the fact that the heavily 
glycosylated CBM 20 has a relatively small amount of β-sheet structure and a relatively high 
amount of unordered structure compared to the other glycoforms (see Figure 2.7).   
 The numerical results for the digest studies, with uncertainties, are reported in full in 
Table app.4.1 in Appendix 4. 
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 3.II.c. Materials and Methods 
 
The thermolysin digestions were performed at 37°C in 100 μL of solution (50 mM Tris-
HCl buffer, 0.5 mM CaCl2, pH = 8.0) with an initial CBM concentration of 270 μM. The CBM  
and thermolysin were initially present in a 20:1 molar ratio. 10 μL aliquots were taken at specific 
time intervals and quenched with an equal volume of 5% AcOH. Each sample was analyzed by 
Quantitative MALDI-TOF Mass Spectrometry (described below) to calculate the change in CBM 
concentration with time. The digestion rate was determined by monitoring and fitting data to the 
first order exponential decay of the full length CBM glycoform over time.  
In the quantative MALDI-TOF experiments, internal reference standard solutions of each 
CBM glycoform were prepared per experiment by serial dilution (10 μL per concentration). To 
all sample aliquots, 150 pmol of a CBM internal standard peptide (Δm/z ≥ 162 Da) in 
H2O:MeCN:AcOH (1:1:3.3% 3 μL) was added. 0.5 μL of each sample was spotted directly on a 
100 well MALDI target plate with 1.126 μL of α-cyano-4-hydroxycinnamic acid (CHCA) matrix 
(6.2 mg/ml) in MeOH:MeCN:H2O (36:56:8) and allowed to air dry (~5 min). Spectra were 
acquired on a Voyager-DETM STR MALDI-TOF mass spectrometer (Applied Biosystems) in 
linear positive ion mode, with 50 shots per spectra. The laser intensity was set to 1950, the 
accelerating voltage was set to 20,000 V, the extraction delay time was 100 ns, and the grid 
voltage was set to 94%. The low mass gate was set to 500 Da and data were collected from 3200-
5000 Da (5500 Da for glycoform 20). An in-house MATLAB program was written to determine 
the ratio of analyte ion intensities between the CBM and the CBM internal standard. From these 
data, a standard linear calibration curve was generated for each experiment to calculate the 
absolute CBM concentration from CBM:CBM internal standard ion intensity ratios.  
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3.III. Thermostability 
 
 3.III.a. Experimental Design 
 
 Variable temperature circular dichroism (CD) was use to investigate whether or not 
mannosylation affected the thermostability of the CBM glycoforms.  CD provides information 
on a protein’s secondary structure by monitoring how the protein affects the ellipticity of 
circularly polarized light.52  By monitoring the CD signal from a protein at a specific wavelength 
as temperature is increased, one can get an idea of how much a protein’s structure changes with 
temperature.53  If an appropriate temperature range is chosen, the protein will go from its folded 
to an unfolded state and the data can be fit by a sigmoidal curve.  The point of inflection of this 
sigmoidal curve (where the second derivative of the curve is equal to zero) is the melting point of 
the protein.  At this point, the protein is 50% folded and 50% unfolded.  A representative variable 
temperature CD melt for the unglycosylated CBM is shown in Figure 3.3 below. 
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Figure 3.3. The variable temperature CD melt for CBM glycoform 1.  Performed between 20 
and 90 °C while monitoring at 217 nm in 10 mM NaOAc pH = 5.2.  The blue line represents the 
experimental data and the red line is the sigmoidal fit that was used to calculate the melting 
temperature. 
 
 3.III.b. Results and Discussion 
 
The results show that O-mannosylation affects CBM thermostability in a site-specific 
manner.   Looking at the mono-glycosylated CBM glycoforms on the left of Figure 3.4, we can 
see that O-mannosylation at Ser-3 leads to the most substantial stabilization, with the increase in 
melting temperature of 11 °C as compared to the unglycosylated CBM 1.  Mannosylation at Ser-
14 also leads to noticeable, but less pronounced stabilization than Ser-3 mannosylation. Thr-1 
mannosylation displayed the least stabilizing ability, and glycosylation at this site actually 
slightly destabilized some of the glycoforms. The glycan size does not appear to be directly 
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related to the magnitude of the stabilizing effect, which is a trend that has been previously noted 
for protein N-glycosylation.
54
  
 
 
Figure 3.4. The thermal melting point of each CBM glycoform.  (Left) The nine mono-
glycosylated CBM glycoforms divided by glycosylation site. (Middle) The multiply-glycosylated 
CBM based on additional glycosylation of glycoforms 5 and 6.  (Right) The three CBM 
glycoforms with all three glycosylation sites occupied by the same glycans. The bars with the 
hatched pattern represent glycoforms with the best overall (stability and binding) properties. 
 
 
 
The correlation between thermostability and glycan density is not very clear (see the 
middle and left of Figure 3.4). All of the multiply glycosylated CBM glycoforms have relatively 
high melting pints between 72 and 78°C, but no noticeable trend exists based on the 
glycosylation patterns.  Very high glycan density does not reduce thermostability as it does to an 
extent with proteolytic stability, but high glycan density does not appear to increase 
thermostability much when the extent of glycosylation goes beyond a disaccharide at Ser-3. 
Mannosylation at Ser-3 leads to the largest increases in thermostability, which suggests 
that something makes the site different than the other glycosylation sites.  A study by Kelly et 
al.55 suggested that interactions between Tyr residues at position i and N-linked glycans attached 
at position i + 2 can lead to substantial thermostabilization in model proteins.  This stabilization 
was purported to be caused by an interaction between the hydrophobic face of the sugar and the 
aromatic ring of the Tyr residue.  Ser-3 in our CBM molecule has a Tyr residue 2 amino acids 
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away, so it is reasonable to hypothesize that a similar sugar-aromatic ring interaction may be 
stabilizing our molecule.  Further studies are being conducted in the Tan Lab to verify this 
hypothesis. 
The numerical results for the CD melting point studies, with uncertainties, are reported in 
full in Table app.4.1 in Appendix 4. 
 
3.III.c. Materials and Methods 
 
All variable temperature CD melts were performed using an Applied 
PhotophysicsChirascan
TM
-plus CD spectrometer and a 0.5 mm quartz cuvette under nitrogen at a 
flow rate of 1 L/min. Lyophilized CBM glycoforms were suspended in 10 mM sodium acetate 
(pH = 5.2) at a concentration of 0.2 mg/ml. The melts were performed by ramping the 
temperature of the sample from 20 to 94°C at a rate of 1 °C/min while monitoring the CD signal 
at 217 nm. The melts resulted in roughly sigmoidal melting curves and the point of inflection of 
the curve was interpreted to be the melting point of the glycoform.56  
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CHAPTER 4 
BINDING STUDIES 
 
4.I. Introduction 
 
 The next natural course of action was to study the effects of glycosylation on the CBM’s 
natural function.  In nature, the CBM binds to cellulose and thus increases the effective 
concentration of  TrCel7A on the surface of crystalline cellulose.  The strength of CBM binding 
appears to be directly correlated to TrCel7A activity, with higher affinity CBMs leading to faster 
and more complete degradation of crystalline cellulose.
57
 Previously performed free energy 
calculations predicted that glycosylation at Thr-1, Ser-3 and Ser-14 would improve the affinity of 
the TrCel7A Family 1 CBM for crystalline cellulose,32 so binding experiments were performed 
using the CBM glycoforms to see if the predictions were true.  Functional studies like these 
crystalline cellulose binding experiments are essential for glyco-engineering efforts because 
improving the proteolytic and theromostability of a protein with glycosylation isn’t really 
meaningful if the glycosylation also impairs protein function.  Fortunately, glycosylation did not 
appear to prevent crystalline cellulose binding for most of the glycoforms and some glycoforms 
with fairly strong binding were identified.   
 
4.II. Experimental Design 
 
An established depletion isotherm method58 was used to study the binding of the CBM 
glycoforms to insoluble cellulose crystals known as bacterial microcrystalline cellulose (BMCC).   
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In short, different concentrations of the CBM analogs were stirred in solution with a fixed 
amount of BMCC crystals at constant temperature for 2 hours, the solutions were centrifuged to 
precipitate the cellulose crystals and bound CBM molecules, and the concentration of unbound 
CBM molecules remaining in each solution was measured.  Various methods were used to 
attempt to quantify the concentration of free CBM in the test solutions after each depletion test, 
and it turned out that the quantitative MALDI technique used in the digestion study was the best 
choice given the instrumentation that was available.  The technique is quite accurate and it 
allowed for the use of very small amounts of CBM in each test.  Using the free CBM 
concentrations from each trial, the binding constants were calculated using the equations given in 
the materials and methods section.  Fortunately, Erick Green developed an automated data 
analysis program that greatly accelerated the binding studies.  A representative BMCC binding 
curve for the unglycosylated CBM 1 is shown in Figure 4.1 below. 
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Figure 4.1. The BMCC binding curve of CBM glycoform 1. Data points represent averaged 
data of at least two trials. Error bars are provided.   The fit line was calculated using equation 4.2 
in the materials and methods section of this chaper.  
 
The adsorption isoforms for the remaining 19 CBM glycoforms are available in Appendix 5. 
 
4.III. Results and Discussion 
 
The results of the binding study are displayed in Figure 4.2 below.  Importantly, the 
binding affinity observed for the unglycosylated CBM is in agreement with the value observed in 
other studies,
58–60
 which validates the experimental techniques utilized in this study. 
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Figure 4.2. The BMCC binding affinity of the CBM glycoforms.  (Left) The nine mono-
glycosylated CBM glycoforms divided by glycosylation site. (Middle) The multiply-glycosylated 
CBM based on additional glycosylation of glycoforms 5 and 6.  (Right) The three CBM 
glycoforms with all three glycosylation sites occupied by the same glycans.  The bars with the 
hatched pattern represent glycoforms with the best overall (stability and binding) properties. 
 
 
 
Looking at the results for the mono-glycosylated glycoforms, reveals that attachment of a 
single mannose to Ser-3 and Ser- 14 substantially increases the binding affinity of the CBM for 
BMCC (by about 4-fold).  The addition of mannose di and tri-saccharides to Ser-3 and Ser-14 
reduces the BMCC binding affinity relative to the glycoforms with just a monosaccharide at 
those positions.  This result is similar to observations by Boraston et al.,
61
 who reported that 
large N-linked glycans were detrimental to a Family 2 CBM cellulose binding.  These results 
may be due to steric hindrance.   It is possible that small glycans improve binding but longer 
glycans can interfere with the interactions between the hydrophobic surface of BMCC and the 
highly conserved Tyr-5, Tyr-31, and Tyr-32 residues on the CBM that are thought to be 
responsible for binding.
61,62
   
Interestingly, the attachment of a single mannose to Thr-1 did not increase the BMCC 
binding affinity of the CBM much (see 2 in Figure 4.2), but the addition of a mannose-mannose 
disaccharide increase the BMCC finding affinity by nearly 4-fold just as the mono-saccharides 
did for Ser-3 and Ser-14.  This observation may be due to the greater distance of Thr-1 from the 
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binding face compared to the other glycosylation sites (see Figure 1.1).  Because of the greater 
distance, a longer glycan is apparently required at Thr-1 in order to increase the binding affinity. 
The addition of a mannose trisaccharide to Thr-1 decreased the BMCC binding affinity of the 
CBM, possibly due to a steric hindrance effect as was hypothesized for the longer glycans at Ser-
3 and Ser-14.  It is also possible that large glycans alter CBM folding in a way that limits binding 
The results of the BMCC binding experiments on the multiply glycosylated CBM 
glycoforms were interesting. As shown in Figure 4.2, the CBM glycoforms with glycans attached 
to all three sites had higher binding affinities than those with just two attachment sites (compare 
13 and 17 to 11, 12, 15 and 16 in Figure 4.2).  As with the mono-glycosylated CBM glycoforms, 
the multiply glycosylated CBM’s with smaller glycans had higher binding affinities than those 
with larger glycans (compare 13 to 19 in Figure 4.2).  In fact, glycoform 13, which has a single 
mannose at Thr-1, Ser-3 and Ser-14, has the strongest binding affinity to BMCC of all of the 
glycoforms.  Apparently, glycosylation does increase BMCC binding affinity as long as the 
glycans remain small, and it is beneficial to have all three of the glycosylation sites occupied.  
These results suggest that mannose monosaccharide attachment to the TrCel7A Family 1 CBM 
glycosylation sites could be a viable way to engineer enzymes with higher binding affinity and 
thus improved catalytic function. 
The numerical results for the binding studies, with uncertainties, are reported in full in 
Table app.4.1 in Appendix 4. 
 
4.IV. Materials and Methods 
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In the BMCC binding experiments, 100-125 μg CBM samples were prepared by 
lyophilization of the pure synthetic products. Stock CBM solutions were prepared by diluting 
sample to 0.5 mg/ml concentration with acetate buffer (50 mM NaOAc, 50 mM NaCl, pH 5.0). 
The stock solutions were serially diluted to produce 1, 2, 3, 4, 8, 12, 16, 20, 30, 40 μM CBM 
samples which were two fold diluted with either acetate buffer (to produce standard curves) or 
bacterial crystalline cellulose obtained from Acetobacter xylinus sub sp. Sucrofermentans 
suspended in acetate buffer (to obtain experimental results).  The samples were stirred in 2 mL 
Eppendorf tubes with 5mm magnetic stir bars for 2 hours at 4°C and 1100 rpm.  The samples 
were then centrifuged at 14,000 x g for 10 minutes at 4°C to remove the BMCC and bound 
cellulose from solution. From each sample two 10 μl aliquots were taken (from the top of the 
solution) and mixed with 3 µL (~150pmol) of a MALDI-MS standard CBM in 
MeCN:H2O:AcOH (1:1:5%). Samples were stored at 4°C until MALDI-TOF data acquisition.  
1.1 μl of Alpha-Cyano-4-hydroxycinnamic acid (6.2 mg/ml in 36% MeOH, 56% MeCN, 
and 8% H2O) was spotted on a gold 100 well MALDI target plate followed immediately by 0.5 
μl of each binding sample.  The spots were allowed to dry for a minimum of 5 minutes. MALDI-
TOF-MS data was acquired on a Voyager-DE™ STR mass spectrometer (Applied Biosystems) 
in linear mode, with 50 shots/spectrum, a mass range of 3200-5000 Da (3200-5500 Da for CBM 
20), and a laser intensity of 1950. For the standard samples, 2-3 spectra were acquired per spot 
and averaged.  For the experimental samples, 1-2 spectra were acquired per spot and averaged.  
All spectra were exported as text files for data analysis. An in house MATLAB code 
developed by Erick Greene was used to determine the free concentration of CBM in the binding 
solutions by comparing the intensities of the experimental and standard mass peaks and then 
comparing the result to a standard curve (obtained using known CBM concentrations). The 
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concentration of free CBM was then used to determine the amount of bound CBM using 
Equation 4.1.  
 
Equation 4.1:        (
    
 
)   
[        (  )      (  )]     ( )
          ( )
 
 
Where bound represents the concentration of CBM bound to crystalline cellulose per unit 
cellulose, initial represents in the initial concentration of CBM present in the binding mixture, 
free represents the concentration of unbound CBM at equilibrium, and vol represents the total 
volume of the binding solution (100 μL for these experiments).  
The resulting data were plotted in Origin 9 Pro and nonlinearly curve fitted to the single-
site Langmuir Equation (Equation 4.2) to determine binding constants.  
 
Equation 4.2:  [     ]   
    [    ]
    
   [    ]
 
 
Where No represents the binding capacity of the CBM glycoform to crystalline cellulose and Kads 
is the association constant of the CBM-cellulose complex.  
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CHAPTER 5 
CONCLUSIONS 
 
5.I. The Effects of Glycosylation on TrCel7A’s Family 1 CBM 
 
The synthetic glycoform library conclusively demonstrated that O-glycosylation 
enhances the stability and cellulose binding affinity of the TrCel7A Family 1 CBM. This study 
further demonstrates how chemical synthesis can be used as a tool to study the effects of 
glycosylation.  The results clearly show that Ser-3 is the glycosylation site with the largest 
impact on CBM stability.  Considering previous studies on N-glycosylation,
49,63
 it is reasonable 
to hypothesize that the large enhancements caused by O-mannosylation at Ser3 might be at least 
partially due to interactions between the mannose residues and nearby Tyr-5.  Further studies are 
being conducted in the Tan Lab to explore this hypothesis.  Analysis of the data also revealed 
two glycoforms—13 and 17, shown with a hatched pattern in Figure 3.2, 3.4 and 4.2—with 
greatly enhanced proteolytic stability, theromostability and BMCC binding affinity.  These 
desirable glycoforms, which have small glycans at all three glycosylation sites, may potentially 
find use in biofuel production applications if an appropriate expression system can be identified. 
Furthermore, the results demonstrate that excessive glycosylation can be detrimental to 
CBM stability and function.  This statement is certainly true for proteolytic stability where the 
most heavily glycosylated glycoform (CBM 20) had a half live of only 5.5 hours whereas 
glycoforms with more intermediate amounts of glycosylation such as glycoforms 14, 17 and 18 
had half-lives between 9 and 10.5 hours.  It is possible that too much glycosylation has less of a 
protective effect because it partially disrupts the protein fold which may expose more or better 
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cleavage sits to the protease.  A similar trend can be observed for BMCC binding affinity where 
glycoform 13, which has a monosaccharide at Thr-1, Ser-3 and Ser-14, has the highest binding 
affinity of all the analogs.  Glycoform 19 has a disaccharide at all of the positions, and it has an 
affinity of less than 1/3 that of glycoform 13.  This result again suggests that a moderate amount 
of glycosylation is most beneficial.  In the case of binding affinity, the reduced binding of 
heavily glycosylated glycoforms is likely due to sterics.  The large glycans probably interfere 
with the binding interaction between the three Tyr residues on the CBM binding face and the 
crystalline surface of BMCC.
61,62
 Interestingly, very high glycan density does not reduce 
thermostability.  However, high glycan density does not appear to increase thermostability much 
when the extent of glycosylation goes beyond a disaccharide at Ser-3.  Apparently excessive 
glycosylation does not limit thermostability as it does the other two properties that were studied.  
Therefore, it is necessary to test several different glyforms in order to determine the 
glycosylation pattern that provides the best balance between stability and function.  Such studies 
allow for the identification of glycoforms with the best overall properties such as glycoforms 13 
and 17 in this study (shown with a hatched pattern in Figure 3.2, 3.4 And 4.2). 
 
5.II. CBM Glycosylation and Biofuels Production 
 
 The results of this study demonstrate that CBM mannosylation confers several properties 
that are potentially beneficial for CBM applications in biofuel production. For instance, the 
enhanced proteolytic stability of the mannosylated CBM glycoforms could help protect them 
from the proteases that fungi secrete during biomass depolymerization.41   Such protection would 
reduce the amount of CBM and cellulase lost during the digestion of cellulose and thus increase 
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biomass conversion rates and yields.  Thermostability is also a desirable trait of industrial 
enzymes as illustrated by the fact that  many studies have engineered cellulases for improved 
thermostability through amino acid substitutions or through domain and sequence shuffling.45,64  
Thermostability is beneficial because it allows biofermentations to be run at higher temperatures 
with less enzyme loss.  Our results indicate that CBM O-mannosylation is an effective way to 
increase CBM theromostability by up to 16 °C. 
The BMCC binding affinity results are especially promising in terms of biofuels 
applications.  As previously mentioned, the strength of CBM binding appears to be directly 
correlated to TrCel7A activity, with higher affinity CBMs leading to faster and more complete 
degradation of crystalline cellulose.
57
 The results show that glycosylated CBMs have binding 
affinities up to 7.4 times greater than the unglycosylated protein, which suggest that O-
mannosylation is a viable way to increase BMCC binding affinity and thus the catalytic 
efficiency of cellulose depolymerization by TrCel7A.  Indeed, the affinity enhancements 
observed in this study are similar to those reported by other researchers who attempted to 
increase CBM binding affinity through amino acid mutations.
21,57
 The added benefit of 
glycosylation over such mutations is that it also improves the stability properties of the protein. 
It is important to note that the results of this study have implications that go beyond 
TrCel7A.  The O-linked glycosylation sites examined in this study are highly conserved across 
Family 1 CBMs,31 suggesting that the enhanced properties from glycosylation observed here 
likely occur throughout this ubiquitous CBM family.  Therefore, glycosylation may be a means 
to improve the properties of a wide range of cellulase CBM’s, and it may find several 
applications in biofuel production. 
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This study illustrates that chemical synthesis is a viable way to produce glycoform 
libraries for the systematic study of glycosylation.  Here, there result was the identification of 
two glycoforms with excellent properties for biofuel production applications.  Additional work 
will have to be done in order to develop expression systems that favor the production of the 
desired glycoforms.  In the future, it should be possible to use this approach to develop 
glycoengineering strategies for other industrially or therapeutically important proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
38 
 
REFERENCES 
 
 
(1)  Brooks, S. a Strategies for analysis of the glycosylation of proteins: current status and 
future perspectives. Molecular biotechnology 2009, 43, 76–88. 
(2)  Shental-Bechor, D.; Levy, Y. Folding of glycoproteins: toward understanding the 
biophysics of the glycosylation code. Current opinion in structural biology 2009, 19, 524–
33. 
(3)  Grünewald, S. Congenital disorders of glycosylation: rapidly enlarging group of 
(neuro)metabolic disorders. Early human development 2007, 83, 825–30. 
(4)  Anthony, R. M.; Nimmerjahn, F.; Ashline, D. J.; Reinhold, V. N.; Paulson, J. C.; Ravetch, 
J. V Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. 
Science (New York, N.Y.) 2008, 320, 373–6. 
(5)  Seipert, R. R.; Dodds, E. D.; Lebrilla, C. B. Exploiting Differential Dissociation 
Chemistries of O-Linked Glycopeptide Ions for the Localization of Mucin-Type Protein 
Glycosylation research articles. 2009, 493–501. 
(6)  Grogan, M. J.; Pratt, M. R.; Marcaurelle, L. a; Bertozzi, C. R. Homogeneous 
glycopeptides and glycoproteins for biological investigation. Annual review of 
biochemistry 2002, 71, 593–634. 
(7)  Nilsson, B. L.; Soellner, M. B.; Raines, R. T. Chemical synthesis of proteins. Annual 
review of biophysics and biomolecular structure 2005, 34, 91–118. 
(8)  Yuan, Y.; Chen, J.; Wan, Q.; Wilson, R. M.; Danishefsky, S. J. Toward fully synthetic, 
homogeneous glycoproteins: advances in chemical ligation. Biopolymers 2010, 94, 373–
84. 
(9)  Sakamoto, I.; Tezuka, K.; Fukae, K.; Ishii, K.; Taduru, K.; Maeda, M.; Ouchi, M.; 
Yoshida, K.; Nambu, Y.; Igarashi, J.; Hayashi, N.; Tsuji, T.; Kajihara, Y. Chemical 
synthesis of homogeneous human glycosyl-interferon-β that exhibits potent antitumor 
activity in vivo. Journal of the American Chemical Society 2012, 134, 5428–31. 
(10)  Wang, P.; Dong, S.; Brailsford, J. a; Iyer, K.; Townsend, S. D.; Zhang, Q.; Hendrickson, 
R. C.; Shieh, J.; Moore, M. a S.; Danishefsky, S. J. At last: erythropoietin as a single 
glycoform. Angewandte Chemie (International ed. in English) 2012, 51, 11576–84. 
(11)  Himmel, M. E.; Ding, S.-Y.; Johnson, D. K.; Adney, W. S.; Nimlos, M. R.; Brady, J. W.; 
Foust, T. D. Biomass recalcitrance: engineering plants and enzymes for biofuels 
production. Science (New York, N.Y.) 2007, 315, 804–7. 
  
39 
 
(12)  Wilson, D. B. Cellulases and biofuels. Current opinion in biotechnology 2009, 20, 295–9. 
(13)  Lynd, L. R.; Weimer, P. J.; Zyl, W. H. Van; Isak, S.; Pretorius, I. S. Microbial Cellulose 
Utilization : Fundamentals and Biotechnology Microbial Cellulose Utilization : 
Fundamentals and Biotechnology. 2002, 66. 
(14)  Bayer, E. a; Belaich, J.-P.; Shoham, Y.; Lamed, R. The cellulosomes: multienzyme 
machines for degradation of plant cell wall polysaccharides. Annual review of 
microbiology 2004, 58, 521–54. 
(15)  Demain, A. L.; Newcomb, M.; Wu, J. H. D. Cellulase, Clostridia, and Ethanol†. 2005, 69, 
124–154. 
(16)  Fontes, C. M. G. a; Gilbert, H. J. Cellulosomes: highly efficient nanomachines designed to 
deconstruct plant cell wall complex carbohydrates. Annual review of biochemistry 2010, 
79, 655–81. 
(17)  Brunecky, R.; Alahuhta, M.; Xu, Q.; Donohoe, B. S.; Crowley, M. F.; Kataeva, I. a; Yang, 
S.-J.; Resch, M. G.; Adams, M. W. W.; Lunin, V. V; Himmel, M. E.; Bomble, Y. J. 
Revealing nature’s cellulase diversity: the digestion mechanism of Caldicellulosiruptor 
bescii CelA. Science (New York, N.Y.) 2013, 342, 1513–6. 
(18)  Boraston, A. B.; Bolam, D. N.; Gilbert, H. J.; Davies, G. J. Carbohydrate-binding 
modules: fine-tuning polysaccharide recognition. The Biochemical journal 2004, 382, 
769–81. 
(19)  Lombard, V.; Golaconda Ramulu, H.; Drula, E.; Coutinho, P. M.; Henrissat, B. The 
carbohydrate-active enzymes database (CAZy) in 2013. Nucleic acids research 2014, 42, 
D490–5. 
(20)  Kraulis, P. J.; Clare, G. M.; Nilges, M.; Jones, T. A.; Pettersson, G.; Knowles, J.; 
Gronenborn, A. M. Domain of Cellobiohydrolase I from Trichoderma reesei . A Study 
Using Nuclear Annealingt. 1989, 7241–7257. 
(21)  Linder, M.; Lindeberg, G.; Reinikainen, T.; Teeri, T. T.; Pettersson, G. The difference in 
affinity between two fungal cellulose-binding domains is dominated by a single amino 
acid substitution. FEBS letters 1995, 372, 96–8. 
(22)  Bu, L.; Nimlos, M. R.; Shirts, M. R.; Ståhlberg, J.; Himmel, M. E.; Crowley, M. F.; 
Beckham, G. T. Product binding varies dramatically between processive and 
nonprocessive cellulase enzymes. The Journal of biological chemistry 2012, 287, 24807–
13. 
(23)  Lehtiö, J.; Sugiyama, J.; Gustavsson, M.; Fransson, L.; Linder, M.; Teeri, T. T. The 
binding specificity and affinity determinants of family 1 and family 3 cellulose binding 
  
40 
 
modules. Proceedings of the National Academy of Sciences of the United States of 
America 2003, 100, 484–9. 
(24)  Deshpande, N.; Wilkins, M. R.; Packer, N.; Nevalainen, H. Protein glycosylation 
pathways in filamentous fungi. Glycobiology 2008, 18, 626–37. 
(25)  Beckham, G. T.; Dai, Z.; Matthews, J. F.; Momany, M.; Payne, C. M.; Adney, W. S.; 
Baker, S. E.; Himmel, M. E. Harnessing glycosylation to improve cellulase activity. 
Current opinion in biotechnology 2012, 23, 338–45. 
(26)  Hui, J. P. M.; Lanthier, P.; White, T. C.; McHugh, S. G.; Yaguchi, M.; Roy, R.; Thibault, 
P. Characterization of cellobiohydrolase I (Cel7A) glycoforms from extracts of 
Trichoderma reesei using capillary isoelectric focusing and electrospray mass 
spectrometry. Journal of Chromatography B: Biomedical Sciences and Applications 2001, 
752, 349–368. 
(27)  Stals, I.; Sandra, K.; Geysens, S.; Contreras, R.; Van Beeumen, J.; Claeyssens, M. Factors 
influencing glycosylation of Trichoderma reesei cellulases. I: Postsecretorial changes of 
the O- and N-glycosylation pattern of Cel7A. Glycobiology 2004, 14, 713–24. 
(28)  Pinto, R.; Carvalho, J.; Mota, M.; Gama, M. Large-scale production of cellulose-binding 
domains. Adsorption studies using CBD-FITC conjugates. Cellulose 2006, 13, 557–569. 
(29)  Payne, C. M.; Resch, M. G.; Chen, L.; Crowley, M. F.; Himmel, M. E.; Taylor, L. E.; 
Sandgren, M.; Ståhlberg, J.; Stals, I.; Tan, Z.; Beckham, G. T. Glycosylated linkers in 
multimodular lignocellulose-degrading enzymes dynamically bind to cellulose. 
Proceedings of the National Academy of Sciences of the United States of America 2013, 
110, 14646–51. 
(30)  Harrison, M. J.; Nouwens, a S.; Jardine, D. R.; Zachara, N. E.; Gooley, a a; Nevalainen, 
H.; Packer, N. H. Modified glycosylation of cellobiohydrolase I from a high cellulase-
producing mutant strain of Trichoderma reesei. European journal of biochemistry / FEBS 
1998, 256, 119–27. 
(31)  Beckham, G. T.; Matthews, J. F.; Bomble, Y. J.; Bu, L.; Adney, W. S.; Himmel, M. E.; 
Nimlos, M. R.; Crowley, M. F. Identification of amino acids responsible for processivity 
in a Family 1 carbohydrate-binding module from a fungal cellulase. The journal of 
physical chemistry. B 2010, 114, 1447–53. 
(32)  Taylor, C. B.; Talib, M. F.; McCabe, C.; Bu, L.; Adney, W. S.; Himmel, M. E.; Crowley, 
M. F.; Beckham, G. T. Computational investigation of glycosylation effects on a family 1 
carbohydrate-binding module. The Journal of biological chemistry 2012, 287, 3147–55. 
(33)  Chen, L.; Tan, Z. A convenient and efficient synthetic approach to mono-, di-, and tri-O-
mannosylated Fmoc amino acids. Tetrahedron Letters 2013, 54, 2190–2193. 
  
41 
 
(34)  Chen, L.; Drake, M. R.; Resch, M. G.; Greene, E. R.; Himmel, M. E.; Chaffey, P. K.; 
Beckham, G. T.; Tan, Z. Specificity of O-glycosylation in enhancing the stability and 
cellulose binding affinity of Family 1 carbohydrate-binding modules. Proceedings of the 
National Academy of Sciences of the United States of America 2014, 1–6. 
(35)  Fields, GB Nobel, R. Solid phase peptide synthesis utilizing 9-fluprenylmethoxycarbonyl 
amino acids. Int. J. Pept. Protein Res. 1990, 35, 161–214. 
(36)  Tan, Z.; Shang, S.; Halkina, T.; Yuan, Y.; Danishefsky, S. J. Toward Homogeneous 
Erythropoietin : Non-NCL-Based Chemical Synthesis of the Gln 78 -Arg 166 
Glycopeptide Domain. 2009, 5424–5431. 
(37)  Johansson, G Stahlberg, Lindenberg,G Engstrom, A Pettersson, G. Isolated fungal 
cellulase terminal domains and a synthetic minimum analogue bind to cellulose. 1989, 
243, 389–393. 
(38)  Mattinen, M. L.; Kontteli, M.; Kerovuo, J.; Linder, M.; Annila, a; Lindeberg, G.; 
Reinikainen, T.; Drakenberg, T. Three-dimensional structures of three engineered 
cellulose-binding domains of cellobiohydrolase I from Trichoderma reesei. Protein 
science : a publication of the Protein Society 1997, 6, 294–303. 
(39)  Hagspiel, K.; Haab, D.; Kubicek, C. P. Applied ° . d Microbiology Biotechnology 
Protease activity and proteolytic modification of cellulases from a Trichoderma reesei Q 
M 9414 selectant. 1989, 61–67. 
(40)  Haab, D.; Hagspiel, K.; Szakmary, K.; Kubicek, C. P. Formation of the extracellular 
proteases from Trichoderma reesei QM 9414 involved in cellulase degradation. Journal of 
Biotechnology 1990, 16, 187–198. 
(41)  Schuster, A.; Schmoll, M. Biology and biotechnology of Trichoderma. Applied 
microbiology and biotechnology 2010, 87, 787–99. 
(42)  Dienes, D.; Börjesson, J.; Hägglund, P.; Tjerneld, F.; Lidén, G.; Réczey, K.; Stålbrand, H. 
Identification of a trypsin-like serine protease from Trichoderma reesei QM9414. Enzyme 
and Microbial Technology 2007, 40, 1087–1094. 
(43)  Banerjee, G.; Scott-Craig, J. S.; Walton, J. D. Improving Enzymes for Biomass 
Conversion: A Basic Research Perspective. BioEnergy Research 2010, 3, 82–92. 
(44)  Yike, I. Fungal proteases and their pathophysiological effects. Mycopathologia 2011, 171, 
299–323. 
(45)  Dana, C. M.; Saija, P.; Kal, S. M.; Bryan, M. B.; Blanch, H. W.; Clark, D. S. Biased 
clique shuffling reveals stabilizing mutations in cellulase Cel7A. Biotechnology and 
bioengineering 2012, 109, 2710–9. 
  
42 
 
(46)  Viikari, L.; Terhi, A. Thermostable Enzymes in Lignocellulose Hydrolysis. 2007, 121–
145. 
(47)  Kim, T.-W.; Chokhawala, H. a; Nadler, D. C.; Nadler, D.; Blanch, H. W.; Clark, D. S. 
Binding modules alter the activity of chimeric cellulases: Effects of biomass pretreatment 
and enzyme source. Biotechnology and bioengineering 2010, 107, 601–11. 
(48)  Hall, M.; Rubin, J.; Behrens, S. H.; Bommarius, A. S. The cellulose-binding domain of 
cellobiohydrolase Cel7A from Trichoderma reesei is also a thermostabilizing domain. 
Journal of biotechnology 2011, 155, 370–6. 
(49)  Price, J. L.; Powers, D. L.; Powers, E. T.; Kelly, J. W. Glycosylation of the enhanced 
aromatic sequon is similarly stabilizing in three distinct reverse turn contexts. Proceedings 
of the National Academy of Sciences of the United States of America 2011, 108, 14127–
32. 
(50)  Boyer, A. E.; Gallegos-Candela, M.; Lins, R. C.; Kuklenyik, Z.; Woolfitt, A.; Moura, H.; 
Kalb, S.; Quinn, C. P.; Barr, J. R. Quantitative mass spectrometry for bacterial protein 
toxins--a sensitive, specific, high-throughput tool for detection and diagnosis. Molecules 
(Basel, Switzerland) 2011, 16, 2391–413. 
(51)  Wu, J.; Chatman, K.; Harris, K.; Siuzdak, G. An automated MALDI mass spectrometry 
approach for optimizing cyclosporin extraction and quantitation. Analytical chemistry 
1997, 69, 3767–71. 
(52)  Greenfield, N. J. Using circular dichrosim spectra to estimate protein secondary structure. 
Nat Protoc. 2006, 1, 2876–2890. 
(53)  Price, J. L.; Shental-bechor, D.; Dhar, A.; Turner, M. J.; Evan, T.; Gruebele, M.; Levy, Y.; 
Kelly, J. W. Context-Dependent Effects of Asparagine Glycosylation on Pin WW Folding 
Kinetics and Theromodynamics. J Am Chem Soc. 2010, 132, 15359–15367. 
(54)  Hanson, S. R.; Culyba, E. K.; Hsu, T.-L.; Wong, C.-H.; Kelly, J. W.; Powers, E. T. The 
core trisaccharide of an N-linked glycoprotein intrinsically accelerates folding and 
enhances stability. Proceedings of the National Academy of Sciences of the United States 
of America 2009, 106, 3131–6. 
(55)  Price, J. L.; Culyba, E. K.; Chen, W.; Murray, A. N.; Hanson, S. R.; Wong, C.-H.; Powers, 
E. T.; Kelly, J. W. N-glycosylation of enhanced aromatic sequons to increase glycoprotein 
stability. Biopolymers 2012, 98, 195–211. 
(56)  Voutilainen, S. P.; Nurmi-Rantala, S.; Penttilä, M.; Koivula, A. Engineering chimeric 
thermostable GH7 cellobiohydrolases in Saccharomyces cerevisiae. Applied microbiology 
and biotechnology 2014, 98, 2991–3001. 
  
43 
 
(57)  Takashima, S.; Ohno, M.; Hidaka, M.; Nakamura, A.; Masaki, H.; Uozumi, T. Correlation 
between cellulose binding and activity of cellulose-binding domain mutants of Humicola 
grisea cellobiohydrolase 1. FEBS letters 2007, 581, 5891–6. 
(58)  Linder, M.; Mattinen, M. L.; Kontteli, M.; Lindeberg, G.; Ståhlberg, J.; Drakenberg, T.; 
Reinikainen, T.; Pettersson, G.; Annila, a Identification of functionally important amino 
acids in the cellulose-binding domain of Trichoderma reesei cellobiohydrolase I. Protein 
science : a publication of the Protein Society 1995, 4, 1056–64. 
(59)  Taylor, C. B.; Payne, C. M.; Himmel, M. E.; Crowley, M. F.; McCabe, C.; Beckham, G. 
T. Binding site dynamics and aromatic-carbohydrate interactions in processive and non-
processive family 7 glycoside hydrolases. The journal of physical chemistry. B 2013, 117, 
4924–33. 
(60)  Guo, J.; Catchmark, J. M. Binding specificity and thermodynamics of cellulose-binding 
modules from Trichoderma reesei Cel7A and Cel6A. Biomacromolecules 2013, 14, 1268–
77. 
(61)  Boraston, A. B.; Warren, R. A. J.; Kilburn, D. G. carbohydrate-binding module from 
Cellulomonas fimi : a functional and mutational analysis. 2001, 430, 423–430. 
(62)  Boraston, A. B.; Sandercock, L. E.; Warren, R. A. J.; Kilburn, D. G. O-Glycosylation of a 
Recombinant Carbohydrate-Binding Module Mutant Secreted by Pichia pastoris. Journal 
of Molecular Microbiology and Biotechnology 2003, 5, 29–36. 
(63)  Ashida, H.; Ozawa, H.; Fujita, K.; Suzuki, S.; Yamamoto, K. Syntheses of mucin-type O-
glycopeptides and oligosaccharides using transglycosylation and reverse-hydrolysis 
activities of Bifidobacterium endo-alpha-N-acetylgalactosaminidase. Glycoconjugate 
journal 2010, 27, 125–32. 
(64)  Heinzelman, P.; Snow, C. D.; Wu, I.; Nguyen, C.; Villalobos, A.; Govindarajan, S.; 
Minshull, J.; Arnold, F. H. A family of thermostable fungal cellulases created by 
structure-guided recombination. Proceedings of the National Academy of Sciences of the 
United States of America 2009, 106, 5610–5.  
 
  
44 
 
APPENDICES 
 
App.1. Synthetic Details and Mass Data for CBM Library 
 
CBM glycoform 1: The unglycosylated peptide was synthesized on a 0.05 mmol scale. After 
SPPS, 168.2 mg of the crude peptide was obtained. 16 mg (4.28 μmol) of the crude peptide was 
dissolved in 80 ml of folding buffer and stirred at room temperature for 12 h. After concentration 
and HPLC purification with a linear gradient of 20→40% acetonitrile in H2O over 30 min, 5.18 
mg of 1 was obtained as a white solid (30% yield based on resin loading). 
 
 
Figure App.1.1. LC-MS trace and ESI-MS of CBM glycoform 1. MS (ESI) Calcd for 
C159H235N43O54S4: [M+2H]
2+
 m/z = 1870.29, [M+3H]
3+
 m/z = 1247.19, [M+4H]
4+
 m/z = 935.65. 
 
CBM glycoform 2: The glycosylated peptide was synthesized on a 0.05 mmol scale. After 
cleavage and lyophilization, 188.7 mg of the crude glycopeptide was obtained. 7 mg (1.71 μmol) 
of it was dissolved in 450 μl of the solution of hydrazine and stirred at room temperature for 30 
min. The reaction was quenched with the solution of AcOH and the pH was adjusted to ~8. The 
resulting solution was diluted by the addition of 40 mL of folding buffer. After folding and 
centrifugal concentration, HPLC purification with a linear gradient of 20→40% acetonitrile in 
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H2O over 30 min afforded the correctly folded 2 (1.04 mg, white solid, 15% yield based on resin 
loading). 
 
Figure App.1.2. LC-MS trace and ESI-MS of CBM glycoform 2. MS (ESI) Calcd for 
C165H245N43O59S4: [M+2H]
2+
 m/z = 1951.32, [M+3H]
3+
 m/z = 1301.21, [M+4H]
4+
 m/z = 976.16. 
 
CBM glycoform 3: The glycosylated peptide was synthesized on a 0.05 mmol scale. After 
cleavage and lyophilization, 164.4 mg of the crude product was obtained. 16 mg (3.67 μmol) of 
it was dissolved in 1000 μL of the hydrazine solution and stirred at room temperature for 30 min 
under helium. The reaction was quenched with acetic acid and the pH was adjusted to between 8 
and 9. The resulting solution was diluted by the addition of 80 mL of folding buffer. After 
folding and centrifugal concentration, HPLC purification with a linear gradient of 20→40% 
acetonitrile in H2O over 30 min afforded the correctly folded 3 (0.64 mg, white solid, 3% yield 
based on resin loading). 
 
Figure App.1.3. LC-MS trace and ESI-MS of CBM glycoform 3. MS (ESI) Calcd for 
C171H255N43O64S4: [M+2H]
2+
 m/z = 2032.35, [M+3H]
3+
 m/z = 1355.23, [M+4H]
4+
 m/z = 
1016.67. 
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CBM glycoform 4: The glycosylated peptide was synthesized on a 0.05 mmol scale. After 
cleavage and lyophilization, 201.6 mg of the crude product was obtained. 16 mg (3.44 μmol) of 
it was dissolved in 1000 μL of the hydrazine solution and stirred at room temperature for 30 min 
under helium. The reaction was quenched with the AcOH solution and the pH was adjusted to 
between 8 and 9. The resulting solution was diluted by the addition of 80 mL of folding buffer. 
After folding and centrifugal concentration, HPLC purification with a linear gradient of 
20→40% acetonitrile in H2O over 30 min afforded the correctly folded 4 (1.95 mg, white solid, 
12% yield based on resin loading). 
 
 
Figure App.1.4. LC-MS trace and ESI-MS of CBM glycoform 4. MS (ESI) Calcd for 
C177H265N43O69S4: [M+2H]
2+
 m/z = 2113.37, [M+3H]
3+
 m/z = 1409.25, [M+4H]
4+
 m/z = 
1057.19. 
 
CBM glycoform 5: The glycosylated peptide was synthesized on a 0.05 mmol scale. After 
cleavage and lyophilization, 179.8 mg of the crude glycopeptide was obtained. 16 mg (3.90 
μmol) of it was dissolved in 1000 μL of the hydrazine solution and stirred at room temperature 
for 30 min under helium. The reaction was quenched with the acetic acid solution and the pH 
was adjusted to between 8 and 9. Then resulting solution was diluted by the addition of 16 mL 
folding buffer. After folding and centrifugal concentration, HPLC purification with a linear 
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gradient of 20→40% acetonitrile in H2O over 30 min afforded the correctly folded 5 (1.12 mg, 
white solid, 6% yield based on resin loading). 
 
 
Figure App.1.5. LC-MS trace and ESI-MS of CBM glycoform 5. MS (ESI) Calcd for 
C165H245N43O59S4: [M+2H]
2+
 m/z = 1951.32, [M+3H]
3+
 m/z = 1301.21, [M+4H]
4+
 m/z = 976.16. 
 
CBM glycoform 6: The glycosylated peptide was synthesized on a 0.05 mmol scale. After 
cleavage and lyophilization, 195.0 mg of the crude glycopeptide was obtained. 16 mg (3.67 
μmol) of it was dissolved in 1000 μL of the hydrazine solution and stirred at room temperature 
for 30 min under helium. The reaction was quenched with the acetic acid solution and the pH 
was adjusted to between 8 and 9. The resulting glycopeptide solution was diluted by the addition 
of 16 mL of folding buffer. After folding and centrifugal concentration, HPLC purification with 
a linear gradient of 20→40% acetonitrile in H2O over 30 min afforded the correctly folded 6 
(1.00 mg, white solid, 6% yield based on resin loading). 
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Figure App.1.6. LC-MS trace and ESI-MS of CBM glycoform 6. MS (ESI) Calcd for 
C171H255N43O64S4: [M+2H]
2+
 m/z = 2032.35, [M+3H]
3+
 m/z = 1355.23, [M+4H]
4+
 m/z = 
1016.67. 
 
CBM glycoform 7: The glycosylated peptide was synthesized on a 0.05 mmol scale. After 
cleavage and lyophilization, 174.0 mg of the crude product was obtained. 16 mg (3.44 μmol) of 
the crude material was dissolved in 1000 μL of the hydrazine solution and stirred at room 
temperature for 30 min under helium. The reaction was quenched with the AcOH solution and 
the pH was adjusted to between 8 and 9. The resulting glycopeptide solution was diluted by the 
addition of 16 mL of folding buffer. After folding and centrifugal concentration, HPLC 
purification with a linear gradient of 20→40% acetonitrile in H2O over 30 min afforded the 
correctly folded 7 (1.09 mg, white solid, 6% yield based on resin loading). 
 
 
Figure App.1.7. LC-MS trace and ESI-MS of CBM glycoform 7. MS (ESI) Calcd for 
C177H265N43O69S4: [M+2H]
2+
 m/z = 2113.37, [M+3H]
3+
 m/z = 1409.25, [M+4H]
4+
 m/z = 
1057.19. 
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CBM glycoform 8: The glycosylated peptide was synthesized on a 0.05 mmol scale. After 
cleavage and lyophilization, 179.3mg of the crude glycopeptide was obtained. 16 mg (3.90 μmol) 
of it was stirred in 1000 μL of the hydrazine solution for 30min under helium. The reaction was 
quenched with the acetic acid solution and the pH was adjusted to between 8 and 9. Then 
resulting glycopeptide solution was diluted by the addition of 16 mL of folding buffer. After 
folding and centrifugal concentration, HPLC purification with a linear gradient of 20→40% 
acetonitrile in H2O over 30 min afforded the correctly folded 8 (1.25 mg, white solid, 7% yield 
based on resin loading). 
 
 
Figure App.1.8. LC-MS trace and ESI-MS of CBM glycoform 8. MS (ESI) Calcd for 
C165H245N43O59S4: [M+2H]
2+
 m/z = 1951.32, [M+3H]
3+
 m/z = 1301.21, [M+4H]
4+
 m/z = 976.16. 
 
CBM glycoform 9: The glycosylated peptide was synthesized on a 0.05 mmol scale. After 
cleavage and lyophilization, 134.7 mg of the crude product was obtained. 16 mg (3.67 μmol) of 
it was stirred in 1000 μL of the hydrazine hydrate solution for 30 min under helium. The reaction 
was quenched with the acetic acid solution and the pH was adjusted to between 8 and 9. The 
resulting glycopeptide solution was diluted by 16 mL of folding buffer. After folding and 
centrifugal concentration, HPLC purification with a linear gradient of 20→40% acetonitrile in 
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H2O over 30 min afforded the correctly folded 9 (0.98 mg, white solid, 4% yield based on resin 
loading). 
 
 
Figure App.1.9. LC-MS trace and ESI-MS of CBM glycoform 9. MS (ESI) Calcd for 
C171H255N43O64S4: [M+2H]
2+
 m/z = 2032.35, [M+3H]
3+
 m/z = 1355.23, [M+4H]
4+
 m/z = 
1016.67. 
 
CBM glycoform 10: The glycosylated peptide was synthesized on a 0.05 mmol scale. After 
cleavage and lyophilization, 202.0 mg of the crude glycopeptide was obtained. 16 mg (3.44 
μmol) of the crude material was dissolved in 1000 μL of the hydrazine solution and stirred at 
room temperature for 30 min under helium. The reaction was quenched with the AcOH solution 
and the pH was adjusted to between 8 and 9. The resulting glycopeptide solution was then 
diluted by the addition of 16 mL of folding buffer. After folding and centrifugal concentration, 
HPLC purification with a linear gradient of 20→40% acetonitrile in H2O over 30 min afforded 
the correctly folded 10 (2.88 mg, white solid, 17% yield based on resin loading). 
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Figure App.1.10. LC-MS trace and ESI-MS of CBM glycoform 10. MS (ESI) Calcd for 
C177H265N43O69S4: [M+2H]
2+
 m/z = 2113.37, [M+3H]
3+
 m/z = 1409.25, [M+4H]
4+
 m/z = 
1057.19. 
 
CBM glycoform 11: The glycosylated peptide was synthesized on a 0.05 mmol scale. After 
cleavage and lyophilization, 225.8 mg of the crude glycopeptide was obtained. 3.5 mg (0.795 
μmol) of the crude material was stirred in 200 μL of the hydrazine solution at room temperature 
for 30 min under helium. The reaction was quenched with the acetic acid solution and the pH 
was adjusted to between 8 and 9. The resulting solution was then diluted by 16 mL of folding 
buffer. After folding and centrifugal concentration, HPLC purification with a linear gradient of 
20→40% acetonitrile in H2O over 30 min afforded the correctly folded 11 (0.45 mg, white solid, 
14% yield based on resin loading). 
 
 
Figure App.1.11. LC-MS trace and ESI-MS of CBM glycoform 11. MS (ESI) Calcd for 
C171H255N43O64S4: [M+2H]
2+
 m/z = 2032.35, [M+3H]
3+
 m/z = 1355.23, [M+4H]
4+
 m/z = 
1016.67. 
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CBM glycoform 12: The glycosylated peptide was synthesized on a 0.05 mmol scale. After 
cleavage and lyophilization, 250 mg of the crude glycopeptide was obtained. 8.0 mg (1.817 
μmol) of the crude material was dissolved in 450 μL of the hydrazine solution and stirred at 
room temperature for 30 min under helium. The reaction was quenched with the acetic acid 
solution and the pH was adjusted to between 8 and 9. The resulting glycopeptide solution was 
then diluted by the addition of 40 mL of folding buffer. After folding and centrifugal 
concentration, HPLC purification with a linear gradient of 20→40% acetonitrile in H2O over 30 
min afforded the correctly folded 12 (1.33 mg, white solid, 20% yield based on resin loading). 
 
 
Figure App.1.12. LC-MS trace and ESI-MS of CBM glycoform 12. MS (ESI) Calcd for 
C171H255N43O64S4: [M+2H]
2+
 m/z = 2032.35, [M+3H]
3+
 m/z = 1355.23, [M+4H]
4+
 m/z = 
1016.67. 
 
CBM glycoform 13: The glycosylated peptide was synthesized on a 0.05 mmol scale. After 
cleavage and lyophilization, 174.0 mg of the crude glycopeptide was obtained. 3.8 mg (0.795 
μmol) of the crude material was dissolved in 200 μL of the hydrazine solution and stirred at 
room temperature for 30 min under helium. The reaction was quenched with the acetic acid 
solution and the pH was adjusted to between 8 and 9. The resulting glycopeptide solution was 
then diluted by the addition of 16 mL of folding buffer. After folding and centrifugal 
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concentration, HPLC purification with a linear gradient of 20→40% acetonitrile in H2O over 30 
min afforded the correctly folded 13 (0.32 mg, white solid, 7% yield based on resin loading). 
 
 
Figure App.1.13. LC-MS trace and ESI-MS of CBM glycoform 13. MS (ESI) Calcd for 
C177H265N43O69S4: [M+2H]
2+
 m/z = 2113.37, [M+3H]
3+
 m/z = 1409.25, [M+4H]
4+
 m/z = 
1057.19. 
 
CBM glycoform 14: The glycosylated peptide was synthesized on a 0.05 mmol scale. After 
cleavage and lyophilization, 167.1 mg of the crude glycopeptide was obtained. 8.6 mg (1.705 
μmol) of it was dissolved in 450 μL of the hydrazine solution and stirred at room temperature for 
30 min under helium. The reaction was quenched with the acetic acid solution and the pH was 
adjusted to between 8 and 9. The resulting glycopeptide solution was then diluted by the addition 
of 40 mL of folding buffer. After folding and centrifugal concentration, HPLC purification with 
a linear gradient of 20→40% acetonitrile in H2O over 30 min afforded the correctly folded 14 
(0.43 mg, white solid, 4% yield based on resin loading). 
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Figure App.1.14. LC-MS trace and ESI-MS of CBM glycoform 14. MS (ESI) Calcd for 
C183H275N43O74S4: [M+2H]
2+
 m/z = 2194.40, [M+3H]
3+
 m/z = 1463.27, [M+4H]
4+
 m/z = 
1097.70. 
 
CBM glycoform 15: The glycosylated peptide was synthesized on a 0.05 mmol scale. After 
cleavage and lyophilization, 178.9 mg of the crude glycopeptide was obtained. 8.0 mg (1.705 
μmol) of it was stirred in 450 μL of the hydrazine solution at room temperature for 30 min under 
helium. The reaction was quenched with the acetic acid solution and the pH was adjusted to 
between 8 and 9. The resulting glycopeptide solution was then diluted by the addition of 40 mL 
of folding buffer. After folding and centrifugal concentration, HPLC purification with a linear 
gradient of 20→40% acetonitrile in H2O over 30 min afforded the correctly folded 15 (0.43 mg, 
white solid, 5% yield based on resin loading). 
 
 
Figure App.1.15. LC-MS trace and ESI-MS of CBM glycoform 15. MS (ESI)Calcd for 
C177H265N43O69S4: [M+2H]
2+
 m/z = 2113.37, [M+3H]
3+
 m/z = 1409.25, [M+4H]
4+
 m/z = 
1057.19. 
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CBM glycoform 16: The glycosylated peptide was synthesized on a 0.05 mmol scale. After 
cleavage and lyophilization, 280 mg of the crude glycopeptide was obtained. 8.0 mg (1.705 
μmol) of it was dissolved in 450 μL of the hydrazine solution and stirred at room temperature for 
30 min under helium. The reaction was quenched with the acetic acid solution and the pH was 
adjusted to between 8 and 9. The resulting glycopeptide solution was then diluted by the addition 
of 40 mL of folding buffer. After folding and centrifugal concentration, HPLC purification with 
a linear gradient of 20→40% acetonitrile in H2O over 30 min afforded the correctly folded 16 
(1.25 mg, white solid, 20% yield based on resin loading). 
 
 
Figure App.1.16. LC-MS trace and ESI-MS of CBM glycoform 16. MS (ESI)Calcd for 
C177H265N43O69S4: [M+2H]
2+
 m/z = 2113.37, [M+3H]
3+
 m/z = 1409.25, [M+4H]
4+
 m/z = 
1057.19. 
 
CBM glycoform 17: The glycosylated peptide was synthesized on a 0.05 mmol scale. After 
cleavage and lyophilization, 170.5 mg of the crude glycopeptide was obtained. 8.6 mg (1.705 
μmol) of the crude material was dissolved in 450 μL of the hydrazine solution and stirred at 
room temperature for 30 min under helium. The reaction was quenched with the acetic acid 
solution and the pH was adjusted to between 8 and 9. The resulting glycopeptide solution was 
then diluted by the addition of 40 mL of folding buffer. After folding and centrifugal 
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concentration, HPLC purification with a linear gradient of 20→40% acetonitrile in H2O over 30 
min afforded the correctly folded 17 (0.40 mg, white solid, 4% yield based on resin loading). 
 
 
Figure App.1.17. LC-MS trace and ESI-MS of CBM glycoform 17. MS (ESI) Calcd for 
C183H275N43O74S4: [M+2H]
2+
 m/z = 2194.40, [M+3H]
3+
 m/z = 1463.27, [M+4H]
4+
 m/z = 
1097.70. 
 
CBM glycoform 18: The glycosylated peptide was synthesized on a 0.05 mmol scale. After 
cleavage and lyophilization, 167.4 mg of the crude glycopeptide was obtained. 9.1 mg (1.705 
μmol) of it was dissolved in 450 μL of the hydrazine solution and stirred at room temperature for 
30 min under helium. The reaction was quenched with the acetic acid solution and the pH was 
adjusted to between 8 and 9. The resulting glycopeptide solution was then diluted by the addition 
of 16 mL of folding buffer. After folding and centrifugal concentration, HPLC purification with 
a linear gradient of 20→40% acetonitrile in H2O over 30 min afforded the correctly folded 18 
(0.40 mg, white solid, 3% yield based on resin loading). 
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Figure App.1.18. LC-MS trace and ESI-MS of CBM glycoform 18. MS (ESI) Calcd for 
C189H285N43O79S4: [M+2H]
2+
 m/z = 2275.42, [M+3H]
3+
 m/z = 1517.28, [M+4H]
4+
 m/z = 
1138.21. 
 
CBM glycoform 19: The glycosylated peptide was synthesized on a 0.05 mmol scale. After 
cleavage and lyophilization, 188.6 mg of the crude glycopeptide was obtained. 16 mg (2.86 
μmol) of the it was dissolved in 1000 μL of the hydrazine solution and stirred at room 
temperature for 30 min under helium. The reaction was quenched with the acetic acid solution 
and the pH was adjusted to between 8 and 9. The resulting glycopeptide solution was then 
diluted by the addition of 16 mL of folding buffer. After folding and centrifugal concentration, 
HPLC purification with a linear gradient of 20→40% acetonitrile in H2O over 30 min afforded 
the correctly folded 19 (0.77 mg, white solid, 4% yield based on resin loading). 
 
 
Figure App.1.19. LC-MS trace and ESI-MS of CBM glycoform 19. MS (ESI) Calcd for 
C195H295N43O84S4: [M+2H]
2+
 m/z = 2356.46, [M+3H]
3+
 m/z = 1571.30, [M+4H]
4+
 m/z = 
1178.73. 
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CBM glycoform 20: The glycosylated peptide was synthesized on a 0.05 mmol scale. After 
cleavage, 165.0 mg of the crude glycopeptide was obtained. 16 mg (2.48 μmol) of it was 
dissolved in 1000 μL of the hydrazine solution and stirred at room temperature for 30 min under 
helium. The reaction was quenched with the acetic acid solution and the pH was adjusted to 
between 8 and 9. The resulting glycopeptide solution was then diluted by the addition of 16 mL 
of folding buffer. After folding and centrifugal concentration, HPLC purification with a linear 
gradient of 20→40% acetonitrile in H2O over 30 min afforded the correctly folded 20 (0.74 mg, 
white solid, 3% yield based on resin loading). 
 
 
Figure App.1.20. LC-MS trace and ESI-MS of CBM glycoform 20. MS (ESI) Calcd for 
C213H325N43O99S4: [M+2H]
2+
 m/z = 2599.53, [M+3H]
3+
 m/z = 1733.35, [M+4H]
4+
 m/z = 
1300.27. 
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App.2.  The Stability and Binding Data for the 20 CBM Glycoforms with Uncertainties 
 
Table App.2.1. Stability and binding data for the 20 CBM glycoforms with uncertainties. 
Half-Life to Thermolysin Degradation and Tm results are presented as mean of three trials ± SD. 
Adsorption affinity consant, Kads and Bmax results are presented as the mean of two trials ± SD. 
*Denotes an averaged value of four trials ± SD. **Weak affinity to cellulose noted, no Kads value 
could be obtained.  
 
 
CBM 
Glycoform 
Half-Life to 
Thermolysin 
Degradation (hr) 
Tm (°C) Kads (μM
-1
) 
Bmax 
(μmol/g) 
1 0.23 ± 0.02 62.2 ± 0.6 0.0894 ± 0.0007* 24 ± 5* 
2 0.28 ± 0.02 61.1 ± 0.7 0.16 ± 0.02 6.5 ± 0.7 
3 0.23 ± 0.02 59.8 ± 0.6 0.34 ± 0.16 25 ± 7 
4 0.208 ± 0.002 65 ± 1 0.06 ± 0.03 22 ± 11 
5 1.09 ± 0.01 70.1 ± 0.9 0.4 ± 0.2 6 ± 1.3 
6 2.13 ± 0.06 73.2 ± 0.7 0.21 ± 0.05 3.6 ± 0.8 
7 2.10 ± 0.05 71.7 ± 0.8 0.13 ± 0.02 3 ± 1.0 
8 0.49 ± 0.01 67.3 ± 0.6 0.35 ± 0.17 5 ± 2 
9 0.55 ± 0.01 65.5 ± 0.7 0.31 ± 0.08 5.9 ± 0.7 
10 0.54 ± 0.01 64.5 ± 0.5 0.25 ± 0.02 10.5 ± 0.6 
11 1.82 ± 0.04 74 ± 1 0.19 ± 0.09 13 ± 6 
12 1.96 ± 0.07 72 ± 1 0.268 ± 0.002 16 ± 1.2 
13 4.33 ± 0 75  ± 2 0.66 ± 0.05 6.6 ± 0.5 
14 10.5 ± 0.8 77.9 ± 0.6 0.373 ± 0.008 9.6 ± 0.11 
15 2.8 ± 0.2 75.4 ± 0.2 0.245 ± 0.003 5.6 ± 0.18 
16 3.6 ± 0.4 75.2 ± 0.5 0.19 ± 0.02 7.1 ± 0.9 
17 9.1 ± 0.6 77.4 ± 0.3 0.58 ± 0.08 4.9 ± 0.15 
18 9.1 ± 0.6 76 ± 2 0.22 ± 0.01 13.4 ± 0.4 
19 3.36 ± 0.08 77 ± 2 0.155 ± 0.012 8.1 ± 0.5 
20 5.5 ± 0.4 75.1 ± 0.8 ~0** ~0** 
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App.3. The BMCC Binding Curves for the 20 CBM Glycoforms 
 
Figure App.3.1.  The binding curve for CBM glycoform 2.  Data were fit using Equation 4.2 
and binding constants are provided in Table App.4.1.  
 
Figure App.3.2.  The binding curve for CBM glycoform 2.  Data were fit using Equation 4.2 
and binding constants are provided in Table App.4.1.  
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Figure App.3.3.  The binding curve for CBM glycoform 4.  Data were fit using Equation 4.2 
and binding constants are provided in Table App.4.1.  
 
Figure App.3.4.  The binding curve for CBM glycoform 5.  Data were fit using Equation 4.2 
and binding constants are provided in Table App.4.1.  
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Figure App.3.5.  The binding curve for CBM glycoform 6.  Data were fit using Equation 4.2 
and binding constants are provided in Table App.4.1.  
 
Figure App.3.6.  The binding curve for CBM glycoform 7.  Data were fit using Equation 4.2 
and binding constants are provided in Table App.4.1.  
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Figure App.3.7.  The binding curve for CBM glycoform 8.  Data were fit using Equation 4.2 
and binding constants are provided in Table App.4.1.  
 
Figure App.3.8.  The binding curve for CBM glycoform 9.  Data were fit using Equation 4.2 
and binding constants are provided in Table App.4.1.  
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Figure App.3.9.  The binding curve for CBM glycoform 10.  Data were fit using Equation 4.2 
and binding constants are provided in Table App.4.1.  
 
Figure App.3.10.  The binding curve for CBM glycoform 11.  Data were fit using Equation 
4.2 and binding constants are provided in Table App.4.1.  
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Figure App.3.11.  The binding curve for CBM glycoform 12.  Data were fit using Equation 
4.2 and binding constants are provided in Table App.4.1.  
 
Figure App.3.12.  The binding curve for CBM glycoform 13.  Data were fit using Equation 
4.2 and binding constants are provided in Table App.4.1.  
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Figure App.3.13.  The binding curve for CBM glycoform 14.  Data were fit using Equation 
4.2 and binding constants are provided in Table App.4.1.  
 
Figure App.3.14.  The binding curve for CBM glycoform 15.  Data were fit using Equation 
4.2 and binding constants are provided in Table App.4.1.  
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Figure App.3.15.  The binding curve for CBM glycoform 16.  Data were fit using Equation 
4.2 and binding constants are provided in Table App.4.1.  
 
Figure App.3.16.  The binding curve for CBM glycoform 17.  Data were fit using Equation 
4.2 and binding constants are provided in Table App.4.1.  
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Figure App.3.17.  The binding curve for CBM glycoform 18.  Data were fit using Equation 
4.2 and binding constants are provided in Table App.4.1.  
 
Figure App.3.18.  The binding curve for CBM glycoform 19.  Data were fit using Equation 
4.2 and binding constants are provided in Table App.4.1.  
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Figure App.3.19.  The binding curve for CBM glycoform 20.  Data were fit using Equation 
4.2 and binding constants are provided in Table App.4.1.  
 
 
 
 
